Immunotherapy for Genitourinary Cancers. Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI
|
|
- Shanon Robinson
- 6 years ago
- Views:
Transcription
1 Immunotherapy for Genitourinary Cancers Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI
2 Disclosures Madison Vaccines Inc co-founder, IP, consultant There will be discussion about the use of products for non-fda approved indications in this presentation
3 Objectives To recognize the role and mechanisms of action of approved immunotherapies for GU cancers Bladder cancer Renal cancer Prostate cancer To recognize other emerging immunological therapies for these diseases To recognize challenges specific to immunebased therapies for the care provider
4 Immunotherapy = The use of cells, molecules, and genes of the immune system for the therapy of infectious disease, autoimmunity, neoplastic diseases, graft-versus-host disease (GVHD), and to prevent the rejection of organ transplants.
5 Case #1 Bladder Cancer You are seeing a 60 y/o man who was diagnosed with superficial bladder cancer 5 years ago. After several courses of resection and intravesical BCG therapy, he developed muscle-invasive disease 2 years ago and underwent radical cystoprostatectomy. He then did well until 4 months ago when he was found to have lung and liver metastases. He started treatment with gemcitabine and cisplatin chemotherapy, but unfortunately had progressive disease after 3 cycles of therapy. You are considering salvage approaches and clinical trials.
6 Bladder Cancer Mucosa confined Recurrent Muscle-invasive Metastatic
7 Bladder Carcinoma in situ BCG First report of intravesical administration of BCG for the treatment of superficial bladder cancer Morales (1976) J. Urol. 116:180 6-week treatment of CIS 43 patients, 84% CR, 62% recurrence free at 5 years Mugiya (2005) Jap J Clin Onc. 35:395
8 Bladder Cancer Ta/T1 - BCG Superior to mitomycin C in reducing risk of recurrence in Ta/T1 tumors 1901 patients from 7 randomized trials (Shelley (2004) BJU 93:485) Mechanism not completely understood Questions remain regarding dose/schedule, strain, use as maintenance therapy Despite treatment, ~50% experience progression to MIBC Adverse effects: nausea, vomiting, weight loss, anorexia, dysuria, polyuria, hematuria, UTI
9 Bladder Cancer Mucosa confined Recurrent Muscle-invasive Metastatic
10 Metastatic Urothelial Cancer Current Chemotherapy Standard Overall survival Time to Progression Median: 7.4 months Median: 13.8 vs months Time to Treatment Failure Median: 5.8 vs. 4.6 months von der Maase (2000) J Clin Onc 18:3068
11 Metastatic Urothelial Cancer 2 nd Line Chemotherapy Phase II docetaxel 100 mg/m 2 every 21d 30 patients 13% PR Duration of response 3-8 months Median survival 9 months Dose reductions necessary for 60% due to AE Phase II weekly docetaxel Median PFS: 1.4 months Median OS: 8.3 months McCaffrey (1997) J Clin Oncol 15:1853 Kim (2016) Clin Genitourin Cancer 14:76
12 T-cell Checkpoint Blockade Drake 10 Nat Rev Imm 10:580
13 Metastatic Urothelial Cancer PD Pathway Inhibitors MPDL3280a IgG1 mab specific for PD-L1 67 patients with metastatic disease 92% previously treated with platinum-based chemotherapy 27% tumors/infiltrating cells express PD-L1 Powles (2014) Nature 515:558
14 Metastatic Urothelial Cancer PD Pathway Inhibitors MPDL3280a administered 15 mg/kg q 3 wks Well tolerated 57% reported treatment related AE 4% grade 3 No grade 4 or 5 events Objective RR after 6 weeks of treatment: 43% for IHC 2/3 tumors (7% CR) 11% for IHC 0/1 tumors Median duration of response not reached Granted breakthrough designation status by FDA in June 2014
15 Metastatic Urothelial Cancer Other PD Pathway Inhibitors Pembrolizumab (anti-pd-1) 10 mg/kg q 2 wk 33 patients with metastatic urothelial cancers 52% > 2 prior therapies; 21% had liver metastases Median follow-up 11 months ORR 24%, 10% CR Response duration weeks (median not reached) Median OS 9.3 months Plimack ESMO 2014 Abstract LBA23
16 Case #2 Renal Cancer You are seeing a 65 y/o woman, in otherwise good health, who underwent nephrectomy 1 year ago for what was found to be a T2 renal cell cancer, Fuhrman grade 2. Staging studies completed prior to hospital discharge at that time showed multiple small pulmonary nodules suspicious for metastatic disease. She entered radiographic surveillance, and 1 month ago was found to have increase in the size of one of the pulmonary nodules. Biopsy confirmed the presence of metastatic renal cell cancer. What are potential treatment options for her at this time?
17 Renal Cancer Surgically resectable Oligo-metastatic Metastatic reemakeup.blogspot.com
18 Renal Cell Cancer IL-2 Early observations of TIL and spontaneous regressions led to exploration of immune therapies IFNα and IL-2 were standard of care for mrcc for ~ 20 years before approval of molecularly targeted agents beginning in 2005 Pooled analysis of 7 phase II trials 255 patients receiving 2 cycles HD IL-2 14% objective responses, 5% CR Median duration 54 months 4% treatment-related mortality rate Fyfe (1995) J Clin Oncol 13:688
19 Renal Cell Cancer PD-pathway inhibitors Phase III CheckMate 025 trial 821 patients with previously treated mrcc (1-2 VEGF tki): Nivolumab (anti-pd-1) 3 mg/kg q 2 wk versus everolimus 10 mg per day Median OS: 25m vs 19.6m ORR: 25% vs 5% Median PFS: 4.6m vs 4.4m Median duration: 23m vs 13.7m Grade 3/4 AE: 19% vs 37% Most common AE with nivolumab was fatigue (2%) Approved by FDA in 2015 Motzer (2015) N Engl J Med 373:1803
20 Renal Cell Cancer Nivolumab Approval indications: Patients with metastatic renal cell cancer who have received prior anti-angiogenic therapy Dosing: 3 mg/kg every 2 weeks Common adverse reactions: Asthenia, cough, nausea, rash, dyspnea, diarrhea, constipation, decreased appetite, back pain, arthralgia Warnings: Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, rash, encephalitis, others
21 Renal Cell Cancer PD-pathway inhibitors Other Trials and Combinations Phase III Nivolumab + Ipilimumab vs. Sunitinib Previously untreated mrcc (CheckMate 214) Phase III Atezolizumab (anti-pd-l1) + Bevacizumab vs. Sunitinib Previously untreated mrcc Phase II Nivolumab pre-surgical resection for mrcc (ADAPTeR) Phase I Nivolumab + Sunitinib or Pazopanib or Ipilimumab Previously untreated mrcc (CheckMate 016) Different combinations with chemotherapy, IFNα, etc Multiple combinations with pembolizumab
22 Renal Cell Cancer Other Immune Therapies Anti-CTLA-4 (ipilimumab) Phase II trial 6/61 with PR 33% with grade 3/4 immune-related toxicities Yang (2007) J Immunoth 30:825 Vaccine (MVA-5T4, TroVax) Phase III trial 733 patients first line mrcc randomized to vaccine vs placebo No difference in OS (median 20.1m vs 19.2m) Magnitude of immune response associated with longer OS Amato (2010) Clin Cancer Res 16:5539
23 Case #3 Prostate Cancer You are seeing a 68 y/o man who was diagnosed with a Gleason 5+4 prostate cancer 5 years ago. He had evidence of metastases to the bone and retroperitoneal lymph nodes, and was started on treatment with leuprolide and bicalutamide. His PSA initially declined, but then began rising two years ago, and the bicalutamide was discontinued. His PSA continued to rise, and he developed pain in his back and ribs, associated with lesions noted on bone scan performed at the same time. He started on docetaxel chemotherapy and completed 9 cycles of therapy 6 months ago. His pain initially resolved, but in the last 2 months has been increasing. His serum PSA has risen from 250 ng/ml to 350 ng/ml in the last month. What are appropriate immunotherapy treatment options for him?
24 Prostate Cancer Clinical Stages Androgen Deprivation Organ Confined Metastatic Disease (D2) Rising PSA Hormone Naïve (D0) Metastatic CR Asymptomatic (D3) Metastatic CR Symptomatic Locally Advanced Rising PSA Castrate- Resistant (D0.5) Timeline
25 Prostate Cancer History of Immunotherapy Animal studies Ab to autologous prostate tissue Cryotherapy - Ab to prostate IL-2 and GM-CSF transfected tumor vaccines (ultimately Cell Genesys) Ab to PSA in D3 patients Primates immunized with vaccinia-psa (ultimately Therion) RNA-loaded DC vaccines DNA vaccines Phase I trial - PSMA peptides on DC (NW Biotherapeutics) PAP-GMCSF vaccine trials started (Dendreon) Phase I trials - carbohydrate vaccines (MSKCC)
26 Prostate Cancer Sipuleucel-T Drake (2010) Nat Rev Immunol. 10:580
27 Prostate Cancer: Sipuleucel-T Phase III IMPACT trial 512 patients with asymptomatic mcrpc randomized to sipuleucel-t vs placebo Median OS: 25.8m vs 21.7m 36-month survival: 31.7% vs 23% No difference in TTP Antibody responses associated with longer survival Most common AE included chills, fever, headache Approved by FDA in 2010 Kantoff (2010) N Engl J Med 363:411
28 Prostate Cancer Sipuleucel-T Approval indications: Patients with asymptomatic to minimally symptomatic castration-resistant metastatic prostate cancer Dosing: Collection and infusion every 2 weeks x 3 Common adverse reactions: Chills, fatigue, fever, back pain, nausea, joint aches, headache Warnings: Infusion reactions, not tested for transmissible infectious diseases, syncope/hypotension, myocardial infarction, thromboembolic events
29 Prostate Cancer: Viral Vaccines Rilimogene galvacirepvec Drake (2010) Nat Rev Immunol. 10:580
30 Prostate Cancer: Viral Vaccines Rilimogene galvacirepvec Randomized phase II trial 125 patients with minimally symptomatic mcrpc Primary endpoint PFS International, randomized phase III trial currently underway Kantoff (2010) J Clin Onc 28:1099
31 Prostate Cancer: T-cell Checkpoint Inhibitors Phase III trial 799 patients with mcrpc after docetaxel therapy randomized to ipilimumab vs placebo + bone-directed XRT (CA ) Primary endpoint OS Time to Progression Median: 11.2 vs. 10 months Kwon (2014) Lancet 15:700
32 Prostate Cancer PD-pathway inhibitors Other Trials and Combinations Phase III Ipilimumab vs placebo in chemotherapynaïve mcrpc Phase I trials with nivolumab or pembrolizumab No evidence of single-agent activity in mcrpc Multiple combinations with ipilimumab or PD-pathway inhibitors with vaccines (including sipuleucel-t), chemotherapy, androgen deprivation, and radiation therapy
33 Summary Approved Immune Therapies Disease Class Agent Bladder/ Urothelial cancer Immunomodulation BCG Renal cell cancer Cytokines IFNα IL-2 T-cell checkpoint inhibitor Nivolumab Prostate cancer Vaccine Sipuleucel-T
34 Summary Approved and Emerging Immune Therapies Disease Class Agent Bladder/ Urothelial cancer Immunomodulation T-cell checkpoint inhibitors Combinations BCG Renal cell cancer Cytokines IFNα IL-2 T-cell checkpoint inhibitor Combinations Atezolizumab (anti-pd-l1) Pembrolizumab (anti-pd1) Nivolumab Pembrolizumab Atezolizumab Prostate cancer Vaccine Sipuleucel-T Rilimogene galvacirepvec Combinations
35 Objectives To recognize the role and mechanisms of action of approved immunotherapies for GU cancers Bladder cancer Renal cancer Prostate cancer To recognize other emerging immunological therapies for these diseases To recognize challenges specific to immunebased therapies for the care provider
36 Opportunities for Patients and Providers Several first in class newer therapies Few adverse events notably fewer in comparison with traditional chemotherapies Survival benefit and/or time to progression at least as great as seen with other approved therapies Tail of the curve durable responses after therapy discontinued (Probably) easily integrated with other therapies
37 Treatment Challenges Cost vs. benefit Different types of AE few, but serious, and can be delayed onset Different types of radiographic response (progression before response or continued (slower?) progression If responses can be durable, how long should one continue treatment? Is there a role for re-treatment? Are there predictors for patients who respond or don t respond? How does one best use these therapies in combination or sequence with other available therapies?
38 Treatment Challenges Unconventional Radiographic Responses 34 patients with previously-treated mrcc, treated with 1 or 10 mg/kg nivolumab every 2 weeks McDermott 2015 J Clin Oncol 33:2013
39 Treatment Challenges For Vaccines How Do We Measure Response? Radiographic responses and PSA responses are not frequent Is long-term stable disease valid? No detection of difference in TTP in two separate trials Probability of non-progression APC8015 (n=82) Placebo (n=45) P = (log-rank) HR = 1.43 (95% CI: 0.98, 2.09) Time from randomization to progression (weeks) Small (2006) J Clin Onc 24:3089 Kantoff (2010) J Clin Onc 28:1099
40 Model of Treatment Effect Arising from Multiple Vaccine Trials Death from tumor Disease Burden Time Adapted from: Madan (2010) Oncologist 15:969
41 Treatment Challenges Predictors of Benefit? PD-L1 expression as predictor of response to PD-pathway blockade Different antibodies and metrics used across trials PD-L1 on tumor versus infiltrating immune cells PD-L1 expression is dynamic and patients with no expression can have response to therapies Will these be useful tests for combination therapies? Others? Are predictive biomarkers even necessary? For sipuleucel-t, and potentially other emerging vaccines, how can we tell if it has worked?
42 Treatment Challenges Sequence with Available Therapies Bladder / Urothelial cancer Will PD-pathway inhibitors replace chemotherapy for firstline treatment of metastatic disease? Renal cell cancer Is there a role for HD IL-2? With PD-pathway inhibitors, VEGF targeted therapies, and mtor inhibitors, what is optimal sequence for mrcc? Role for adjuvant therapy? What about debulking neprectomy? Prostate cancer How do we sequence sipuleucel-t and emerging therapies with AR-targeted therapies?
43 Conclusions Several first in class newer immune-based therapies are available for the treatment of genitourinary cancers Several other novel immune-based therapies are in advanced stages of clinical testing To date, there has been a favorable safety-to-benefit ratio compared with traditional chemotherapies These therapies provide different considerations for the treating physician with respect to identification of benefit, duration of therapy, and sequence with other available treatment agents
The Role of Immunotherapy in Prostate Cancer: What s Trending?
The Role of Immunotherapy in Prostate Cancer: What s Trending? Douglas G. McNeel, MD, PhD University of Wisconsin Carbone Cancer Center Madison, Wisconsin Prostate cancer rationale for immune therapies
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationIMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationChallenging Genitourinary Tumors: What s New in 2017
Challenging Genitourinary Tumors: What s New in 2017 David J. Vaughn, MD Genitourinary Medical Oncology Professor Please note that some of the studies reported in this presentation were presented as an
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationIs Immune Therapy the Holy Grail in Metastatic Kidney Cancer?
Is Immune Therapy the Holy Grail in Metastatic Kidney Cancer? New Frontiers in Urologic Oncology 8-2016 Mayer Fishman, MD PhD Member, Moffitt Cancer Center Department of Genitourinary Oncology Professor,
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmunotherapy in genitourinary malignancies
Mehta et al. Journal of Hematology & Oncology (2017) 10:95 DOI 10.1186/s13045-017-0457-4 REVIEW Immunotherapy in genitourinary malignancies Kathan Mehta 1,2, Keyur Patel 1 and Rahul A. Parikh 1,2,3* Open
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationLecture 17: Vaccines (Therapeutic and Prophylactic Types)
Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Therapeutic vaccines Bacillus Calmette Guerin (BCG; TheraCys) Very old agent initially developed as vaccine for MTB. Uses: Superficial bladder
More informationSummary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN
Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, 2009 Nasdaq: DNDN PROVENGE sipuleucel-t is an autologous active cellular immunotherapy that activates
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationImmunotherapy Therapy for Prostate Cancer
2006 Prostate Health Education Network African American Prostate Cancer Disparity Summit Immunotherapy Therapy for Prostate Cancer Glen W. McWilliams, MD Chief of Urology James J. Peters VAMC Assistant
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationDendritic Cell Based Cancer Vaccine Development
Dendritic Cell Based Cancer Vaccine Development November 10, 2005 CVCWG Meeting Rob Hershberg, MD, PhD Chief Medical Officer 1 Meeting the challenges of developing cancer vaccines-- APC8015 (Provenge TM
More informationImmunotherapy Overview, Rationale, and Role in Clinical Practice
Immunotherapy Overview, Rationale, and Role in Clinical Practice Financial Disclosure Bradi L. Frei, PharmD, BCOP, BCPS has no relevant financial relationships with commercial interests to disclose. OBJECTIVES
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationImmunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Lawrence G. Lum, MD, DSc Karmanos Cancer Institute and Wayne State University Advances in Cancer Immunotherapy
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmunotherapy and new agents in CRPC. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Immunotherapy and new agents in CRPC Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas, Astrazeneca, Bayer, Clovis,
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationCANCER IMMUNOTHERAPY Presented by John A Keech Jr DO MultiCare Regional Cancer Center
CANCER IMMUNOTHERAPY 2018 Presented by John A Keech Jr DO MultiCare Regional Cancer Center Successful anti-cancer immunity is autoimmunity Green, The Scientist, 2014 Immunotherapy strategies Cancer vaccines
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationMAMTA PARIKH, MD, MS CHALLENGING CASE #2: GU CANCER & STATE OF THE ART: CASTRATION RESISTANT PROSTATE CANCER
MAMTA PARIKH, MD, MS CHALLENGING CASE #2: GU CANCER & STATE OF THE ART: CASTRATION RESISTANT PROSTATE CANCER NO RELEVANT FINANCIAL RELATIONSHIPS IN THE PAST TWELVE MONTHS BY PRESENTER OR SPOUSE/PARTNER.
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationAfrican American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study
African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study Jennifer Harris, PharmD Medical Science Liaison Bavarian Nordic, Inc. Prostate
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationSummary... 2 GENITOURINARY TUMOURS - PROSTATE... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3 Custirsen provides no additional survival benefit to cabazitaxel/prednisone
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More information2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationRationale for Multimodality Therapy for High Risk Localized Prostate Cancer
Rationale for Multimodality Therapy for High Risk Localized Prostate Cancer 100 80 60 Cancer Death Rates for Men, US 1930-2002 Rate Per 100,000 Lung William K. Oh, M.D. 40 Stomach Colon & rectum Prostate
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationPolicy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043.
Cellular Immunotherapy forr Prostate Cancer Policy Number: 8.01.53 Origination: 11/2010 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for cellular immunotherapy for prostate
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationCANCER IMMUNOTHERAPY GUIDELINES (PROSTATE)
CANCER IMMUNOTHERAPY GUIDELINES (PROSTATE) An Annotated Bibliography of the Literature (in order of topic) With Authors Additions SOCIETY FOR IMMUNOTHERAPY OF CANCER JULY 3, 2015 Table of Contents TOPIC:
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More information